Universe Pharmaceuticals Inc cash flow statement

In fiscal 2025, Universe Pharmaceuticals Inc's operations generated −$5.05bn of cash; it spent $267m on capital projects, leaving free cash flow of −$5.32bn.

Cash flow statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Universe Pharmaceuticals Inc: cash flow statement, annual
Fiscal year	2019Sept 2019	2020Sept 2020	2021Sept 2021	2022Sept 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025
Cash from operations	0.0	0.0	−0.0	−0.0	1.1	−9.5	−5.1
Depreciation and amortisation	0.0	0.0	0.0	0.0	0.5	0.5	0.5
Capital spending	0.0	0.0	0.0	0.0	0.0	0.2	0.3
Free cash flow	0.0	0.0	−0.0	−0.0	1.1	−9.7	−5.3
Dividends paid	0.0	—	—	—	—	—	—
Shares issued	—	—	—	—	—	25.0	15.0

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: UPC vs VTRS HLN vs UPC BHC vs UPC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Universe Pharmaceuticals Inc's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Universe Pharmaceuticals Inc.